AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis

The body’s natural process for healing wounds has led AsclepiX Therapeutics to a novel approach to treating diseases of the eye. The startup is now gearing up to test its technology in humans, and it has raised $35 million in Series A financing to support its research.